Darunavir is a protease inhibitor that has become the preferred medicine of its class in current HIV treatment guidance. It is given alongside a booster and is valued for holding up strongly against resistance. This guide explains what darunavir is, how it works, where it fits in treatment today, and the points a treating doctor keeps under review.
Darunavir is often abbreviated to DRV, and is usually written together with its booster, for example darunavir/ritonavir.
| Important note This article is general information about medicines used in HIV care. It does not include dosing instructions and is not a substitute for medical advice. All HIV medicines are prescription-only and are selected, started, and changed by a qualified doctor. |
Quick Summary / Key Takeaways
|
Darunavir is a protease inhibitor that has become the preferred medicine of its class in current HIV treatment guidance. It is given alongside a booster and is valued for holding up strongly against resistance. Darunavir is often abbreviated to DRV.
Darunavir belongs to the protease inhibitor class described in the guide to protease inhibitors. It acts at the final stage of the viral life cycle, and is always given with a booster and alongside other antiretroviral medicines.
HIV uses an enzyme called protease at the end of its life cycle, cutting long protein chains into the pieces needed to assemble new, infectious particles. Darunavir blocks that enzyme. New particles are still produced, but they cannot mature into a form capable of infecting other cells.
Darunavir is cleared from the body relatively quickly on its own. A booster, most often ritonavir, slows that clearance so the medicine remains at effective levels. When used this way, ritonavir is not the main treatment medicine, as explained in the guide to ritonavir as a booster.
Guidance updated in January 2026 names darunavir with ritonavir as the preferred protease inhibitor where a change of regimen is needed. Several features explain that position: a high barrier to resistance, reliable effectiveness when taken consistently, and a profile that suits situations where earlier treatment has been reviewed.
Darunavir is used mainly when a regimen is being changed rather than for people starting treatment, where integrase inhibitor regimens are preferred. Its place in subsequent treatment is discussed in second-line ART and when to switch.
Darunavir is generally manageable with medical guidance. Reported effects include nausea, loose stools or other digestive effects, headache, changes in cholesterol and other lipid measures, and skin rash (usually mild and appearing early).
| Myth | Fact |
|---|---|
| Darunavir is taken without a booster. | It is given with a booster such as ritonavir to remain at effective levels. |
| The booster is the main treatment medicine. | The booster raises darunavir levels; darunavir is the active treatment. |
| Darunavir is a first-line medicine for everyone. | It is mainly used when a regimen is being changed. |
| Resistance develops quickly with darunavir. | It has a high barrier to resistance, which is a key advantage. |
| An early rash always means treatment must stop. | Rash is usually mild and early; it needs medical review rather than stopping independently. |
| When to Consult a Doctor Medical advice is appropriate before starting or changing darunavir, where digestive effects or a rash persist, and whenever another medicine is being started. A consultation can be arranged through an HIV doctor consultation. |
Darunavir blocks the enzyme HIV needs to assemble mature, infectious particles, and is given with a booster so it remains at effective levels. Its high barrier to resistance is why current guidance names it the preferred protease inhibitor. It is used mainly when treatment is being changed, always under the direction of a treating doctor.
For expert guidance, TAAL+ Healthcare offers HIV treatment & ART care and a confidential HIV doctor consultation.
Darunavir is a protease inhibitor used as part of combination HIV treatment, mainly when a regimen is being changed. Current guidance names it the preferred medicine of its class.
It blocks protease, the enzyme HIV uses to cut protein chains into the pieces needed to assemble new infectious particles. New particles are still produced but cannot mature.
Darunavir is cleared from the body relatively quickly on its own. Ritonavir acts as a booster that slows this clearance so darunavir stays at effective levels.
Guidance updated in January 2026 names darunavir with ritonavir as the preferred option mainly because of its high barrier to resistance and reliable effectiveness.
Reported effects include nausea, loose stools and other digestive effects, headache, changes in cholesterol measures, and an early mild rash. Most are manageable with medical guidance.
Boosted regimens affect how the body processes a wide range of medicines, so the treating doctor reviews everything being taken.
It is mainly used when a regimen is being changed rather than for people starting treatment, where integrase inhibitor regimens are preferred.
Rash is usually mild and appears early. It should be reviewed by the treating doctor rather than stopping treatment independently.
+91 98925 15959
Before You Go
The HIV Test Kit Is Still FREE
A private HIV self-test, delivered in plain packaging. Result in 20 minutes, at home. No cost, no clinic visit, and a TAAL+ doctor on call whichever way it goes.
Offer valid only in India till 30 September 2026. T&Cs apply.
